Trials / Completed
CompletedNCT03993132
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
Cardiovascular Outcomes, and Mortality in Danish Patients With Type 2 Diabetes Who Initiate Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA): A Danish Nationwide Comparative Effectiveness Study [EMPLACEtm]
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 26,774 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin | new users (initiators) of Empagliflozin |
| DRUG | Liraglutide | initiators of Liraglutide |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2022-06-16
- Completion
- 2022-06-16
- First posted
- 2019-06-20
- Last updated
- 2024-02-12
- Results posted
- 2024-02-12
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03993132. Inclusion in this directory is not an endorsement.